$COLL
COLLEGIUM PHARMACEUTICAL, INC

2020 Q3 Form 10-Q Financial Statement

#000155837020012836 Filed on November 05, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2019 Q3 2019 Q2
Revenue $79.18M $72.94M $75.04M
YoY Change 8.55% 3.94% 2.71%
Cost Of Revenue $30.98M $46.75M $48.65M
YoY Change -33.73% 1.62% 3.88%
Gross Profit $48.19M $26.19M $26.39M
YoY Change 84.03% 8.35% 0.62%
Gross Profit Margin 60.87% 35.9% 35.16%
Selling, General & Admin $26.43M $30.07M $28.94M
YoY Change -12.12% -10.09% -7.49%
% of Gross Profit 54.83% 114.83% 109.66%
Research & Development $2.141M $2.491M $2.459M
YoY Change -14.05% 30.62% 9.92%
% of Gross Profit 4.44% 9.51% 9.32%
Depreciation & Amortization $17.00M $3.800M $3.900M
YoY Change 347.37% -88.31% -88.0%
% of Gross Profit 35.27% 14.51% 14.78%
Operating Expenses $28.57M $32.56M $31.39M
YoY Change -12.27% -7.9% -6.33%
Operating Profit $19.63M -$6.375M -$5.008M
YoY Change -407.86% -43.01% -31.33%
Interest Expense $8.063M $228.0K $236.0K
YoY Change 3436.4% -96.11% -96.17%
% of Operating Profit 41.08%
Other Income/Expense, Net
YoY Change
Pretax Income $11.57M -$6.109M -$4.712M
YoY Change -289.33% -62.98% -63.92%
Income Tax $280.0K $0.00
% Of Pretax Income 2.42%
Net Earnings $11.29M -$6.109M -$4.712M
YoY Change -284.74% -62.98% -63.92%
Net Earnings / Revenue 14.25% -8.38% -6.28%
Basic Earnings Per Share $0.33 -$0.18 -$0.14
Diluted Earnings Per Share $0.32 -$0.18 -$0.14
COMMON SHARES
Basic Shares Outstanding 34.54M 33.48M 33.40M
Diluted Shares Outstanding 35.07M 33.48M 33.40M

Balance Sheet

Concept 2020 Q3 2019 Q3 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $165.4M $153.8M $148.7M
YoY Change 7.54% 10.01% 11.22%
Cash & Equivalents $165.4M $153.8M $148.7M
Short-Term Investments
Other Short-Term Assets $3.100M $2.800M $4.600M
YoY Change 10.71% -17.65% -17.86%
Inventory $17.15M $8.760M $9.953M
Prepaid Expenses
Receivables $76.47M $84.38M $81.28M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $262.1M $249.8M $244.6M
YoY Change 4.94% 14.06% 13.07%
LONG-TERM ASSETS
Property, Plant & Equipment $17.75M $11.58M $10.37M
YoY Change 53.26% 92.98% 223.97%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $147.0K $204.0K $198.0K
YoY Change -27.94% 2.0% 98.0%
Total Long-Term Assets $381.7M $54.19M $57.02M
YoY Change 604.35% -87.32% -87.52%
TOTAL ASSETS
Total Short-Term Assets $262.1M $249.8M $244.6M
Total Long-Term Assets $381.7M $54.19M $57.02M
Total Assets $643.8M $304.0M $301.6M
YoY Change 111.81% -52.98% -55.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.491M $11.98M $10.94M
YoY Change -45.82% 2.4% -41.49%
Accrued Expenses $17.71M $20.61M $24.52M
YoY Change -14.09% -86.38% -81.31%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $47.30M $2.900M $1.900M
YoY Change 1531.03% 262.5%
Total Short-Term Liabilities $242.4M $201.5M $196.3M
YoY Change 20.33% -28.09% -25.85%
LONG-TERM LIABILITIES
Long-Term Debt $219.8M $8.600M $9.600M
YoY Change 2455.81% -19.63% -16.52%
Other Long-Term Liabilities $9.000M $9.600M $9.900M
YoY Change -6.25% -96.63% -96.85%
Total Long-Term Liabilities $228.8M $18.20M $19.50M
YoY Change 1157.14% -93.84% -94.02%
TOTAL LIABILITIES
Total Short-Term Liabilities $242.4M $201.5M $196.3M
Total Long-Term Liabilities $228.8M $18.20M $19.50M
Total Liabilities $471.2M $219.7M $215.8M
YoY Change 114.44% -61.83% -63.47%
SHAREHOLDERS EQUITY
Retained Earnings -$340.1M -$357.7M -$351.6M
YoY Change -4.92%
Common Stock $35.00K $34.00K $33.00K
YoY Change 2.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $172.7M $84.26M $85.82M
YoY Change
Total Liabilities & Shareholders Equity $643.8M $304.0M $301.6M
YoY Change 111.81% -52.98% -55.21%

Cashflow Statement

Concept 2020 Q3 2019 Q3 2019 Q2
OPERATING ACTIVITIES
Net Income $11.29M -$6.109M -$4.712M
YoY Change -284.74% -62.98% -63.92%
Depreciation, Depletion And Amortization $17.00M $3.800M $3.900M
YoY Change 347.37% -88.31% -88.0%
Cash From Operating Activities $34.20M $6.000M $14.70M
YoY Change 470.0% -85.65% -73.56%
INVESTING ACTIVITIES
Capital Expenditures -$2.400M -$1.300M -$900.0K
YoY Change 84.62% -51.85% 12.5%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$2.400M -$1.300M -$900.0K
YoY Change 84.62% -51.85% 12.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -12.00M 400.0K 0.000
YoY Change -3100.0% -101.21% -100.0%
NET CHANGE
Cash From Operating Activities 34.20M 6.000M 14.70M
Cash From Investing Activities -2.400M -1.300M -900.0K
Cash From Financing Activities -12.00M 400.0K 0.000
Net Change In Cash 19.80M 5.100M 13.80M
YoY Change 288.24% -16.39% 193.62%
FREE CASH FLOW
Cash From Operating Activities $34.20M $6.000M $14.70M
Capital Expenditures -$2.400M -$1.300M -$900.0K
Free Cash Flow $36.60M $7.300M $15.60M
YoY Change 401.37% -83.6% -72.34%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2019Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2019Q3 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2020Q3 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33678840
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34577129
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001267565
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37372
dei Entity Registrant Name
EntityRegistrantName
Collegium Pharmaceutical, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
VA
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
03-0416362
dei Entity Address Address Line1
EntityAddressAddressLine1
100 Technology Center Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Stoughton
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02072
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
713-3699
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
COLL
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
34582324
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
165423000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
170019000
CY2020Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
76466000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
72953000
CY2020Q3 us-gaap Inventory Net
InventoryNet
17146000
CY2019Q4 us-gaap Inventory Net
InventoryNet
9643000
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3097000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3105000
CY2020Q3 us-gaap Assets Current
AssetsCurrent
262132000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
255720000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17746000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11854000
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8572000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9047000
CY2020Q3 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
352699000
CY2019Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
29503000
CY2020Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
2547000
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
147000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
178000
CY2019Q3 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
43066000
us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
54316000
CY2020Q3 us-gaap Assets
Assets
643843000
CY2019Q4 us-gaap Assets
Assets
306302000
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
6491000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6247000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17710000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
33480000
CY2020Q3 coll Accrued Rebates Returns And Discounts Current
AccruedRebatesReturnsAndDiscountsCurrent
170246000
CY2019Q4 coll Accrued Rebates Returns And Discounts Current
AccruedRebatesReturnsAndDiscountsCurrent
157549000
CY2020Q3 us-gaap Loans Payable Current
LoansPayableCurrent
47281000
CY2019Q4 us-gaap Loans Payable Current
LoansPayableCurrent
3833000
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
709000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
656000
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
242437000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
201765000
CY2020Q3 us-gaap Long Term Loans Payable
LongTermLoansPayable
121967000
CY2019Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
7667000
CY2020Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
97795000
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8958000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9438000
CY2020Q3 us-gaap Liabilities
Liabilities
471157000
CY2019Q4 us-gaap Liabilities
Liabilities
218870000
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34577129
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33678840
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
35000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
34000
CY2020Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
512756000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
447297000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-340105000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-359899000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
172686000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
87432000
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
643843000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
306302000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
79176000
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
72942000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
233745000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
222498000
CY2020Q3 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
14188000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.58
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.62
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34540126
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33481923
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34346071
us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
133508000
CY2020Q3 us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
16795000
CY2019Q3 us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
3688000
us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
43885000
us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
11064000
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
30983000
CY2019Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
46754000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
98201000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
144572000
CY2020Q3 us-gaap Gross Profit
GrossProfit
48193000
CY2019Q3 us-gaap Gross Profit
GrossProfit
26188000
us-gaap Gross Profit
GrossProfit
135544000
us-gaap Gross Profit
GrossProfit
77926000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2141000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2491000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7300000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7942000
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
26426000
CY2019Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
30072000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
87008000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
91359000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
28567000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
32563000
us-gaap Operating Expenses
OperatingExpenses
94308000
us-gaap Operating Expenses
OperatingExpenses
99301000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
19626000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6375000
us-gaap Operating Income Loss
OperatingIncomeLoss
41236000
us-gaap Operating Income Loss
OperatingIncomeLoss
-21375000
CY2020Q3 us-gaap Interest Expense
InterestExpense
8063000
CY2019Q3 us-gaap Interest Expense
InterestExpense
228000
us-gaap Interest Expense
InterestExpense
21145000
us-gaap Interest Expense
InterestExpense
698000
CY2020Q3 us-gaap Investment Income Net
InvestmentIncomeNet
3000
CY2019Q3 us-gaap Investment Income Net
InvestmentIncomeNet
494000
us-gaap Investment Income Net
InvestmentIncomeNet
229000
us-gaap Investment Income Net
InvestmentIncomeNet
1552000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
11566000
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6109000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
20320000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-20521000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
280000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
526000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
11286000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-6109000
us-gaap Net Income Loss
NetIncomeLoss
19794000
us-gaap Net Income Loss
NetIncomeLoss
-20521000
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.33
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33360272
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.32
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
589000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
535000
us-gaap Share Based Compensation
ShareBasedCompensation
15700000
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.56
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.62
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35069188
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33481923
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35054777
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33360272
us-gaap Net Income Loss
NetIncomeLoss
19794000
us-gaap Net Income Loss
NetIncomeLoss
-20521000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
43885000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
11064000
us-gaap Share Based Compensation
ShareBasedCompensation
12562000
coll Operating Lease Payments Non Cash
OperatingLeasePaymentsNonCash
49000
coll Operating Lease Payments Non Cash
OperatingLeasePaymentsNonCash
409000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
6427000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3513000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
6434000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
9315000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
943000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-39000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2314000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
244000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-169000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-15231000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-7228000
coll Increase Decrease In Accrued Rebates Returns And Discounts
IncreaseDecreaseInAccruedRebatesReturnsAndDiscounts
12697000
coll Increase Decrease In Accrued Rebates Returns And Discounts
IncreaseDecreaseInAccruedRebatesReturnsAndDiscounts
20480000
coll Increase Decrease In Operating Lease Asset And Liabilities
IncreaseDecreaseInOperatingLeaseAssetAndLiabilities
734000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-676000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
71365000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
12127000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
368226000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4065000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5549000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-372291000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5549000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
758000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
817000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6394000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
531000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2169000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
721000
us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
192117000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
138277000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
25000000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
11500000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
298877000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
627000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2049000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
7205000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
170019000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
146633000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
167970000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
153838000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
165423000
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
153838000
CY2020Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
2547000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
167970000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
153838000
us-gaap Interest Paid Net
InterestPaidNet
14718000
us-gaap Interest Paid Net
InterestPaidNet
543000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
738000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
552000
coll Noncash Or Part Noncash Acquisition Accrued Royalties Discharged
NoncashOrPartNoncashAcquisitionAccruedRoyaltiesDischarged
1145000
coll Inventory Used In Construction And Installation Of Property And Equipment
InventoryUsedInConstructionAndInstallationOfPropertyAndEquipment
1812000
coll Receivable From Stock Option Exercises In Other Current Assets
ReceivableFromStockOptionExercisesInOtherCurrentAssets
5000
coll Operating Lease Assets Assumed
OperatingLeaseAssetsAssumed
9957000
coll Operating Lease Liabilities Assumed
OperatingLeaseLiabilitiesAssumed
10691000
us-gaap Derivatives Embedded Derivatives
DerivativesEmbeddedDerivatives
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Embedded Derivatives</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company accounts for derivative financial instruments as either equity or liabilities in accordance with Accounting Standards Codification Topic 815, <i style="font-style:italic;">Derivatives and Hedging</i>, based on the characteristics and provisions of each instrument. Embedded derivatives are required to be bifurcated from the host instruments and recorded at fair value if the derivatives are not clearly and closely related to the host instruments on the date of issuance. The Company’s term notes (see Note 10) and convertible notes (see Note 11) contain certain features that, in accordance with ASC 815, are not clearly and closely related to the host instrument and represent derivatives that are required to be re-measured at fair value each reporting period. The Company determined that the estimated fair value of the derivatives at issuance and as of September 30, 2020 were not material based on a scenario-based cash flow model that uses unobservable inputs that reflect the Company’s own assumptions. Should the Company’s assessment of the probabilities around these scenarios change, including due to changes in market conditions, there could be a change to the fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other than the aforementioned changes, there have been no material changes in the Company’s significant accounting policies, other than the adoption of accounting pronouncements below, as compared to the significant accounting policies described in the Annual Report.</p>
CY2019Q3 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2020Q3 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
us-gaap Revenue Practical Expedient Incremental Cost Of Obtaining Contract
RevenuePracticalExpedientIncrementalCostOfObtainingContract
true
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
79176000
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
72942000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
233745000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
222498000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
11286000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-6109000
us-gaap Net Income Loss
NetIncomeLoss
19794000
us-gaap Net Income Loss
NetIncomeLoss
-20521000
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34540126
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33481923
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34346071
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33360272
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35069188
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33481923
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35054777
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33360272
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.33
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.58
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.62
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.32
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.56
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.62
CY2020Q3 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
142672000
CY2020Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
97795000
CY2020Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
3784000
CY2019Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
795000
CY2020Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
2654000
CY2019Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1427000
CY2020Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
10708000
CY2019Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
7421000
CY2020Q3 us-gaap Inventory Net
InventoryNet
17146000
CY2019Q4 us-gaap Inventory Net
InventoryNet
9643000
CY2020Q3 coll Inventory Used In Construction And Installation Of Property And Equipment
InventoryUsedInConstructionAndInstallationOfPropertyAndEquipment
1199000
coll Inventory Used In Construction And Installation Of Property And Equipment
InventoryUsedInConstructionAndInstallationOfPropertyAndEquipment
1812000
coll Summary Of Costs Included In Acquired Asset
SummaryOfCostsIncludedInAcquiredAsset
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Acquisition consideration:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Base purchase price</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:27.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 375,000</p></td></tr><tr><td style="vertical-align:bottom;width:69.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Cash paid for inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 6,030</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Transaction costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:27.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 6,297</p></td></tr><tr><td style="vertical-align:bottom;width:69.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Reduction for 2020 cash transferred to Assertio under the prior Nucynta Commercialization Agreement<sub style="font-size:7.5pt;vertical-align:sub;">(1)</sub></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (13,071)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Reduction for accrued royalty obligation discharged upon closing<sub style="font-size:7.5pt;vertical-align:sub;">(1)</sub></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:27.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (1,145)</p></td></tr><tr><td style="vertical-align:bottom;width:69.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Total acquisition consideration:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 373,111</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;text-align:left;">Represents </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;text-align:left;">$14,216</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;text-align:left;"> total reduction to the base purchase price comprising of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;text-align:left;">$13,071</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;text-align:left;"> of cash payments transferred to Assertio under the prior Nucynta Commercialization Agreement as well as a reduction for discharged pre-acquisition accrued royalties based on sales from January 1, 2020 through closing. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company then allocated the consideration transferred to the individual assets acquired on a relative fair value basis as summarized in the table below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:68.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets acquired:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Nucynta Intangible Asset</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:27.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 367,081</p></td></tr><tr><td style="vertical-align:bottom;width:68.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,030</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:68.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total consideration allocated to assets acquired:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:27.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 373,111</p></td></tr></table>
CY2018Q4 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
8043000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
126340000
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
16795000
CY2019Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3688000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
43885000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
11064000
us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P5Y3M18D
CY2020Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
16795000
CY2020Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
67181000
CY2020Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
67181000
CY2020Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
67181000
CY2020Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
67181000
CY2020Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
67180000
CY2020Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
352699000
CY2020Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
6587000
CY2019Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
21893000
CY2020Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
3408000
CY2019Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
4047000
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1883000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1154000
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1580000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3180000
CY2020Q3 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
1492000
CY2019Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
1650000
CY2020Q3 coll Accrued Product Taxes And Fees Current
AccruedProductTaxesAndFeesCurrent
1420000
CY2020Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
558000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
308000
CY2020Q3 us-gaap Interest Payable Current
InterestPayableCurrent
472000
CY2019Q4 us-gaap Interest Payable Current
InterestPayableCurrent
473000
CY2020Q3 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
310000
CY2019Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
775000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17710000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
33480000
CY2020Q1 coll Adjustments To Additional Paid In Capital Convertible Debt Equity Component Of Transaction Costs
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtEquityComponentOfTransactionCosts
1773000
CY2020Q3 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
8043000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
87432000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4454000
CY2020Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
357000
CY2020Q1 coll Stock Withheld For Employee Taxes Upon Vesting Of Restricted Stock Units Value
StockWithheldForEmployeeTaxesUponVestingOfRestrictedStockUnitsValue
-1358000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4951000
CY2020Q1 coll Adjustments To Additional Paid In Capital Convertible Debt Equity Component Of Transaction Costs
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtEquityComponentOfTransactionCosts
1773000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
44777000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
450000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
141063000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1626000
CY2020Q2 coll Stock Withheld For Employee Taxes Upon Vesting Of Restricted Stock Units Value
StockWithheldForEmployeeTaxesUponVestingOfRestrictedStockUnitsValue
-564000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5584000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
8058000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
155767000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
314000
CY2020Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
401000
CY2020Q3 coll Stock Withheld For Employee Taxes Upon Vesting Of Restricted Stock Units Value
StockWithheldForEmployeeTaxesUponVestingOfRestrictedStockUnitsValue
-247000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5165000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
11286000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
172686000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
91585000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
246000
CY2019Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
444000
CY2019Q1 coll Stock Withheld For Employee Taxes Upon Vesting Of Restricted Stock Units Value
StockWithheldForEmployeeTaxesUponVestingOfRestrictedStockUnitsValue
-488000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4263000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-9700000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
86350000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
58000
CY2019Q2 coll Stock Withheld For Employee Taxes Upon Vesting Of Restricted Stock Units Value
StockWithheldForEmployeeTaxesUponVestingOfRestrictedStockUnitsValue
-35000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4162000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-4712000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
85823000
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
232000
CY2019Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
373000
CY2019Q3 coll Stock Withheld For Employee Taxes Upon Vesting Of Restricted Stock Units Value
StockWithheldForEmployeeTaxesUponVestingOfRestrictedStockUnitsValue
-198000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4137000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-6109000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
84258000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5165000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4137000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15700000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12562000
CY2020Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
39175000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M6D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
12.78
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.98
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
7201000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
183000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.013
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.024
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.662
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.632
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
coll Employee Stock Purchase Plan Purchase Price Percentage
EmployeeStockPurchasePlanPurchasePricePercentage
0.85
us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
67512
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
758000
us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
74142
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
817000
CY2020Q3 coll Employee Stock Purchase Plan Compensation Expense
EmployeeStockPurchasePlanCompensationExpense
89000
CY2019Q3 coll Employee Stock Purchase Plan Compensation Expense
EmployeeStockPurchasePlanCompensationExpense
120000
coll Employee Stock Purchase Plan Compensation Expense
EmployeeStockPurchasePlanCompensationExpense
260000
coll Employee Stock Purchase Plan Compensation Expense
EmployeeStockPurchasePlanCompensationExpense
293000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
280000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
526000
CY2020Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.024
CY2019Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.026
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
280000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
526000
us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2020Q3 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2019Q3 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2020Q3 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0

Files In Submission

Name View Source Status
0001558370-20-012836-index-headers.html Edgar Link pending
0001558370-20-012836-index.html Edgar Link pending
0001558370-20-012836.txt Edgar Link pending
0001558370-20-012836-xbrl.zip Edgar Link pending
coll-20200930.xsd Edgar Link pending
coll-20200930x10q.htm Edgar Link pending
coll-20200930x10q001.jpg Edgar Link pending
coll-20200930x10q_htm.xml Edgar Link completed
coll-20200930xex31d1.htm Edgar Link pending
coll-20200930xex31d2.htm Edgar Link pending
coll-20200930xex32d1.htm Edgar Link pending
coll-20200930xex32d2.htm Edgar Link pending
coll-20200930_cal.xml Edgar Link unprocessable
coll-20200930_def.xml Edgar Link unprocessable
coll-20200930_lab.xml Edgar Link unprocessable
coll-20200930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending